BioRestorative Bolsters ThermoStem Patent Protection in Australia
Event summary
- BioRestorative Therapies secured patent allowance No. 2020265664 from IP Australia.
- The patent covers a method for creating 3D brown adipose-derived stem cell aggregates (BADSC) for ThermoStem®.
- The patent provides broad protection for BioRestorative’s allogeneic, off-the-shelf ThermoStem® technology.
- The allowance strengthens BioRestorative’s IP portfolio in the obesity and metabolic disorders space.
- The company aims to develop ThermoStem® as a cell-based alternative to GLP-1 drugs.
The big picture
BioRestorative is attempting to carve out a niche in the rapidly expanding obesity and metabolic disorder treatment market, currently dominated by GLP-1 receptor agonists. The company’s ThermoStem® technology represents a bet on cell-based therapies as a potentially safer and longer-lasting alternative, but faces significant hurdles in clinical development and commercialization against a backdrop of intense competition and high patient expectations. Securing this Australian patent is a tactical win, but doesn't guarantee success.
What we're watching
- Commercialization
- The success of ThermoStem® hinges on demonstrating clinical efficacy and safety in human trials, a process that could take several years and require significant investment.
- GLP-1 Competition
- The GLP-1 market is dominated by established players; BioRestorative must prove ThermoStem® offers a compelling advantage – longer duration, improved safety – to gain meaningful market share.
- IP Defense
- While this Australian patent strengthens BioRestorative’s position, ongoing patent challenges and potential infringement suits from competitors remain a risk to their competitive advantage.
